A5053961676- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Cancer Treatment and Pharmacology
- Antiplatelet Therapy and Cardiovascular Diseases
- Chemotherapy-induced cardiotoxicity and mitigation
- COVID-19 Clinical Research Studies
- Acute Myocardial Infarction Research
- COVID-19 and healthcare impacts
- Acute Myeloid Leukemia Research
- Microscopic Colitis
- Chronic Myeloid Leukemia Treatments
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Intestinal and Peritoneal Adhesions
- Central Venous Catheters and Hemodialysis
- Neuroendocrine Tumor Research Advances
- Celiac Disease Research and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Parvovirus B19 Infection Studies
- Testicular diseases and treatments
- Neurofibromatosis and Schwannoma Cases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cardiac Arrhythmias and Treatments
- COVID-19 diagnosis using AI
- Chemotherapy-related skin toxicity
Vestre Viken Hospital Trust
2018-2025
Oslo University Hospital
2021-2023
Johnson University
2023
Rutgers, The State University of New Jersey
2023
There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed efficacy and safety apixaban 30 months, after initial 6 months full-dose treatment.We included 298 patients with any type VTE a single arm interventional clinical trial. All were treated (5 mg twice daily) months. Total 196 active treatment continued 2.5 daily another The main endpoints recurrent VTE, major bleeding clinically relevant...
Introduction It is unclear how drug-interaction with apixaban influences recurrent venous thromboembolism (VTE) and bleedings in cancer patients. Methods A post-hoc analysis of a single-arm interventional clinical trial on treatment patients VTE to investigate whether the occurrence any endpoints could be associated concurrent use an interacting drug. Drugs taken by during period were categorized as either increasing bleeding risk, thrombosis both or neither. Results 298 divided into groups...
BACKGROUND Emerging reports indicate a high incidence of venous thromboembolism in patients hospitalised for SARS-CoV-2 pneumonia during the spring 2020 pandemic. The pronounced pulmonary and systemic inflammatory responses observed these may contribute to transient hypercoagulable state. In this setting, embolism cause further respiratory distress clinical deterioration. CASE PRESENTATION We describe course three admitted with infection distress, where was detected hospitalisation. Two...
Dermatitis herpetiformis and coeliac disease are gluten-sensitive diseases that share immunopathological mechanisms. Neurological disorders reported in both diseases, being more frequent disease. is rare paediatric populations only sporadic cases with neurological dysfunction reported. Uncertainty exists as to whether early treatment may stop or reverse symptoms. We describe here the case of a child presenting rash ataxia, diagnosed dermatitis herpetiformis, whom symptoms signs regressed...
de siste 12 månedene.Grundig anamnese
Figure:Forest plot of treatment effect DOAs versus LMWHs on major bleeding in each study and overall, expressed as HR 95% CI RHR to estimate the impact fragility CI.A greater than 1 means that is associated with a reduction effect. Conclusion(s):This meta-analysis suggests MB could be affected by advanced age CAT patients.No other modifiers were identified, presence cancer being probably most important criteria.Before additional data confirm this result, there no reason date restrict...
Venous thromboembolism is a common complication of cancer. The prevalence varies according to cancer type and increases proportionally with the stage In past 15−20 years, low molecular weight heparin has been recommended as first-line treatment. New international guidelines now allow for use direct factor Xa inhibitors both prophylaxis treatment venous thromboembolism. Prophylaxis should general rule only be initiated in patients moderate high risk. Bleeding risk assessment important before...